Loading stock data…
$9.19-0.08 (-0.86%)
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients.
Candel Therapeutics, Inc. in the Healthcare sector is trading at $9.19 with a market capitalization of $896M. Wall Street consensus targets $21.75 (8 analysts), implying a +136.7% move over the next 12 months. The stock is currently 34% below its 52-week high of $14.00, remaining 13.2% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 15 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$26.72M↓ | -$16.26M↓ | -$15.66M↓ | -$13.21M↓ | -$11.18M |
| Net Income | -$38.91M↓ | -$8.86M↑ | -$29.50M↓ | -$11.27M↓ | -$4.80M |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the...